Roflumilast Cream Effective for Long-Term Pediatric Atopic Dermatitis Control

The long-term utilize of roflumilast cream 0.05%, a nonsteroidal phosphodiesterase-4 inhibitor, appears to be both safe and effective in managing mild to moderate atopic dermatitis in young children, according to research published in Pediatric Dermatology on March 19, 2026. The findings offer a potentially valuable option for caregivers seeking sustained relief for children aged 2 to 5, a population where treatment options have historically been limited due to concerns surrounding long-term topical corticosteroid use.

Expanding Treatment Options for Young Children

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition that causes intense itching and a rash. It significantly impacts quality of life for both children and their families. “Traditionally, there have been concerns with using topical corticosteroids continuously, the variations in strengths and the steroid withdrawal phenomena, as these concerns complicate a plan for using topical corticosteroids in long-term care regimens,” explains Dr. Lawrence F. Eichenfield, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and a member of the Healio Dermatology Peer Perspective Board. Dr. Eichenfield highlighted the need for alternative treatments that can provide sustained control without the potential drawbacks of prolonged steroid use.

Roflumilast (Zoryve, Arcutis) was approved by the FDA for this age group in late 2025, offering a new avenue for treatment. The recent study, INTEGUMENT-OLE, builds on the earlier INTEGUMENT-PED trial, evaluating the long-term efficacy and safety of the cream in a real-world setting.

Study Design and Key Findings

The INTEGUMENT-OLE study involved 562 children who had previously participated in the INTEGUMENT-PED trial. The study, published in Pediatric Dermatology, divided participants into two groups: 382 continued receiving roflumilast cream daily, even as 180 switched from a vehicle cream (placebo) to roflumilast. Parents or caregivers applied the cream to all affected areas, excluding the scalp. A subset of patients who achieved Investigator Global Assessment (IGA) scores of 0 (clear skin) or 1 (almost clear) at week 4 were transitioned to a twice-weekly application schedule to assess maintenance of disease control.

The primary endpoints of the study focused on measuring disease improvement at week 56. Researchers assessed IGA success (defined as a score of 0 or 1 plus a 2-point or greater improvement), IGA 0 or 1, EASI-75 (a 75% improvement in the Eczema Area and Severity Index), and a 4-point or greater improvement on the Worst Itch-Numeric Rating Scale (for those with a baseline score of 4 or higher).

The results demonstrated significant efficacy in both groups. Over half of the participants – 53.8% in the continued roflumilast group and 55% in the switch-to-roflumilast group – achieved IGA success at week 56. Similarly, 65% and 62.2%, respectively, achieved IGA scores of 0 or 1, indicating substantial skin clearance. A large majority, 71.9% and 76%, respectively, reached EASI-75, signifying a significant reduction in disease severity. Approximately 41% of participants in both groups experienced a clinically meaningful reduction in itch.

Twice-Weekly Application and Disease Control

Notably, the study also explored the feasibility of a less frequent application schedule. Approximately 30% of participants achieved IGA 0 at or after week 4 and were switched to twice-weekly roflumilast. These patients maintained disease control for a median duration of 238 days (95% CI, 146-331 days), suggesting that a reduced application frequency may be sufficient for long-term maintenance in some individuals.

Safety Profile and Adverse Events

The study also provided reassuring data regarding the safety of roflumilast cream. Treatment-related adverse events were reported in only 2.5% of participants. Dr. Eichenfield emphasized that over 97% of children experienced no evidence of local irritation, with very few reports of stinging or burning. Serious adverse events unrelated to the study treatment occurred in 18 participants, with the most common being infection-related presentations like upper respiratory tract infections, nasopharyngitis, and fever.

Implications for Clinical Practice and Future Research

These findings suggest that roflumilast cream 0.05% represents a valuable addition to the treatment armamentarium for pediatric atopic dermatitis. The ability to achieve sustained disease control with a nonsteroidal agent, and the potential for a less frequent application schedule in some patients, offer significant benefits for both children and their caregivers. As Dr. Eichenfield noted, the option to use roflumilast “as needed or as a proactive way to maintain disease control” provides flexibility in managing this chronic condition.

Further research may focus on identifying predictors of response to roflumilast and optimizing treatment strategies for individual patients. Ongoing surveillance will also be crucial to monitor the long-term safety and efficacy of the cream in real-world clinical practice. The FDA will likely continue to monitor post-market surveillance data to ensure continued safety and efficacy.

For parents and caregivers seeking more information about atopic dermatitis and treatment options, consulting with a qualified dermatologist is recommended. Resources from organizations like the National Eczema Association (https://nationaleczema.org/) can also provide valuable support and education.